Is CVS Caremark a Buy?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

With shares of CVS Caremark (NYSE:CVS) trading around $73, is CVS an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

CVS Caremark is a pharmacy and healthcare provider in the United States. The company operates in three business segments: Pharmacy Services, Retail Pharmacy, and Corporate. The products and services offered at CVS Caremark stores may be deemed as essential by many consumers in the United States. As CVS Caremark provides an efficient and affordable healthcare and pharmacy experience, look for it to see rising profits.

CVS Caremark’s first-quarter earnings jumped 18 percent as generic drugs and an acquisition helped the drugstore chain and pharmacy benefits manager weather rough winter storms. The company runs the nation’s second largest drugstore chain, with many of its nearly 7,700 stores on the East Coast and in the Midwest, areas blasted by snow storms and sub-zero temperatures this past winter. CVS Caremark said that weather, plus a weaker flu season compared to last year, hurt sales at its established stores. CEO Larry Merlo told analysts during a Friday conference call that the company normally doesn’t blame the weather when it explains results, but it was making an exception. “This quarter, the amount of extreme weather was so abnormal that, quite frankly, it’s hard not to talk about it,” he said.

CVS Caremark Corp. also runs one of the biggest pharmacy benefits management operations, and that segment played a large role in its growth during the quarter. Sales from that unit, which runs prescription drug plans for employers and other clients, climbed more than 10 percent to top $20 billion in the quarter. It was helped in part by rising drug prices, as well as the company’s acquisition of the drug infusion business Coram. Growth in generic drug also helped the company’s bottom line, as it has done for several quarters now for CVS and other drugstores. Generics, which are cheaper than brand-name drugs, provide a wider margin between the cost for the pharmacy to purchase the drugs and the reimbursement it receives. CVS earned $1.13 billion, or 95 cents per share, in the three months that ended March 31. That compares with earnings of $954 million, or 77 cents per share, in last year’s quarter. Revenue climbed 6 percent to $32.69 billion. Adjusted results totaled $1.02 per share. That was 2 cents shy of Wall Street expectations and a penny lower than what the company expected.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business